
    
      Overweight/obese males, pre- and post-menopausal females with insulin resistance, 30-70 years
      of age will be recruited. Following screening, eligible men and women will be randomly
      assigned to either amiloride (max dose 5mg) or placebo in a double-blinded design manner.

      After randomization, subjects will be scheduled for an outpatient visit to the undergo
      baseline assessment of arterial stiffness (carotid femoral pulse wave velocity - cfPWV) and
      endothelial function (brachial popliteal artery flow mediated dilation). Subject assessment
      will be repeated at 12 weeks and at 24 weeks.
    
  